Ardelyx, Inc.
ARDX•NASDAQ•Healthcare•Biotechnology

About Ardelyx

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOMichael Raab
Founded2007
IPO DateJune 19, 2014
Employees395
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.ardelyx.com
Phone510 745 1700
Address
400 Fifth Avenue, Suite 210 Waltham, Massachusetts 02451 United States

Corporate Identifiers

CIK0001437402
CUSIP039697107
ISINUS0396971071
SIC2834

Leadership Team & Key Executives

Michael G. Raab
President, Chief Executive Officer and Director
Elizabeth A. Grammer Esq.
Chief Legal and Administrative Officer and Secretary
Dr. Laura A. Williams M.D., M.P.H.
Chief Patient Officer
Mike Kelliher
Chief Business Officer
Sue Hohenleitner
Chief Financial Officer
Joseph Reilly
Senior Vice President of Finance and Principal Accounting Officer
Caitlin Lowie
Vice President of Corporate Communications and Investor Relations
James P. Brady
Chief Human Resources Officer
Eric Duane Foster
Chief Commercial Officer
Dr. Edward Conner M.D.
Chief Medical Officer